Pancreatic cancer is one of the hardest diagnoses in medicine, which is what makes two 2026 developments so encouraging. Patients given the experimental drug elraglusib alongside standard chemotherapy were twice as likely to be alive after a year, and their risk of death dropped by 38 percent.

A second drug, daraxonrasib, outperformed chemotherapy and let patients live three to four times longer without their disease progressing — eight to nine months, on average. For a cancer that has long resisted progress, it's a real opening.